BRTX BioRestorative Therapies, Inc.

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

BRTX — —

What changed

Recent filings, trades and moves
Key stats
About
Industry (SIC)
SERVICES-MISC HEALTH & ALLIED SERVICES, NEC (8090) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
14
List Date
1997-12-22
CIK
0001505497
Next Earnings
2026-11-25
EPS Forecast
($2.60) (1 est.)
Headquarters
Melville, NY
Homepage
https://www.biorestorative.com

BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection wit…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan---19.48%8.09%-5.23%59.73%-6.56%7.31%
Feb--37.97%-10.06%-35.19%-35.59%-80.14%-24.60%
Mar---8.08%21.86%-8.00%17.88%27.27%10.19%
Apr---23.41%13.47%1.43%-1.12%-21.02%-6.13%
May--2.03%26.21%-8.76%-1.40%104.89%24.59%
Jun---34.22%-17.57%57.36%-7.47%-7.48%-1.88%
Jul---9.93%-36.76%-22.73%-9.82%-46.91%-25.23%
Aug--7.55%-23.88%7.19%30.50%2.27%4.73%
Sep--2.16%-22.17%12.45%-16.18%-41.25%-13.00%
Oct---4.41%-4.35%-1.27%7.69%-38.31%-8.13%
Nov-14.53%-5.25%6.67%-1.92%-28.09%-11.49%*-9.10%
Dec-25.30%-17.66%-5.95%-4.67%12.98%---8.12%
Total-36.15%-61.26%-49.72%-29.25%-5.58%-93.84%-45.97%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.48
SMA 50: $1.89
SMA 200: $4.82
Current: $1.31
EMA 12: $1.44
EMA 26: $1.59
MACD: -0.1560 | Signal: 0.0212
BEARISH
ADX (14): 34.42
TREND
+DI: 11.57
−DI: 22.70

Momentum Oscillators

RSI (14): 31.70
NEUTRAL
Stoch %K: 2.85
Stoch %D: 10.58
Williams %R: -91.67

Volume & Volatility

BB Upper: $1.66
BB Lower: $1.29
NEUTRAL
OBV: 43,022,073
Vol SMA 20: 26,882
Vol ROC: -57.12%
ATR: $0.14
True Range: $0.10
HV 20: 100.1%
HV 30: 92.7%
HV 60: 105.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis

LLM Stock Analysis Report: BRTX

Executive Summary

Overall Assessment: BEARISH (Confidence Level: 6/10)

Key Drivers:

  • Bearish technical indicators, including MACD and RSI
  • High volatility and beta relative to the market
  • Recent negative news sentiment and lack of earnings data

Primary Risks:

  • Continued price decline due to bearish momentum
  • Increased volatility and potential for sharp moves

Investment Thesis: BRTX is a high-risk stock with significant technical and fundamental challenges. While recent positive news headlines provide some support, the overall trend remains bearish. Investors should exercise caution and consider hedging strategies or reevaluating their investment position.

Recent News Sentiment Impact: The recent positive news sentiment has provided some support to the stock price, but the impact is limited given the bearish technical indicators and high volatility.

Technical Analysis

Trend Direction:

  • Short-term: BEARISH
  • Medium-term: BEARISH
  • Long-term: NEUTRAL (trend unclear)

Support/Resistance Levels:

  • Lower band: $2.83 (Bollinger Bands)
  • Middle band: $3.98 (SMA 50)
  • Upper band: $5.12 (Bollinger Bands)

Momentum Signals: RSI: 24.29 (oversold), MACD: -0.55 / Signal: -0.08 / Histogram: -0.47 (bearish), RSI momentum: -1.43

Volume Analysis: Volume SMA 20: 22660.56, On-Balance Volume (OBV): 42931204.17, Volume Rate of Change: 71.07%

News & Sentiment Analysis

Recent Headlines Summary:

  • Positive news headlines highlighting company's advancements in regenerative spine program and bio-cosmeceuticals
  • Neutral news headlines related to public offering and conference participation
  • No negative news headlines found

Sentiment Assessment: Aggregate news sentiment: POSITIVE ( weighted average of positive headlines)

Catalyst Identification: No immediate or near-term catalysts identified, but the company's advancements in regenerative spine program could provide a medium-term catalyst.

Market Narrative: The positive news sentiment and company advancements are not sufficient to overcome the bearish technical indicators and high volatility. The market narrative remains neutral-to-bearish.

Risk & Volatility Assessment

Risk Interpretation: Beta: 1.64 (high-risk stock relative to the market)

Volatility Regime: High volatility - stock moves more than the market

Options Market Signals: IV rank: N/A, put/call ratios: N/A, unusual activity: N/A

Downside Protection: Support levels: $2.83 (Bollinger Bands), risk management considerations: stop-loss at $3.00

Market Context & Positioning

Sector Performance: Relative strength vs sector/market: NEUTRAL

Institutional Activity: Volume patterns suggesting institutional interest: MIXED

Correlation Analysis: How stock moves relative to market (R-squared interpretation): 0.15 (high correlation)

Relative Valuation: Position within trading range: BEARISH (stock below its middle band)

Key Levels & Action Items

Critical Price Levels:

  • Support: $2.83 (Bollinger Bands)
  • Resistance: $3.98 (SMA 50)

Breakout/Breakdown Levels: None identified

Time-Sensitive Catalysts: No immediate or near-term catalysts identified, but the company's advancements in regenerative spine program could provide a medium-term catalyst.

Risk Management: Stop-loss at $3.00, position sizing considerations: reduce exposure or consider hedging strategies

Generated

BRTX Options Activity & IV Rank

Loading options activity...
Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
ATM — / Put —
30 DTE / 10d put —
— pts EXTREME
ATM — / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 1.4162
Alpha: -215.20%
Correlation: 0.1347
R-Squared: 1.8%
Stock Volatility: 146.1%
Market Volatility: 13.9%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own BRTX
1 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$103K
0.00%
#5795 of 6285+14.5%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

BRTX Institutional Ownership (13F)

Filings for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

16 filers657,519 shares$356.91K value
# Filer Shares Value % of Total % of Float Period
1 XTX Topco Ltd 286,504 $107.73K 30.18% — 2026-06-30
2 Citadel Advisors LLC Custodian 273,304 $102.76K 28.79% — 2026-06-30
3 Jane Street Group, LLC Custodian 27,156 $63.27K 17.73% — 2026-09-30
4 HRT FINANCIAL LP 14,194 $33.00K 9.25% — 2026-09-30
5 Vanguard Fiduciary Trust Co 9,065 $21.12K 5.92% — 2026-09-30
6 Northern Trust Corp Custodian 24,009 $9.03K 2.53% — 2026-06-30
7 UBS Group AG Custodian 3,422 $7.97K 2.23% — 2026-09-30
8 Susquehanna International Group, LLP Custodian 16,068 $6.04K 1.69% — 2026-06-30
9 Vanguard Capital Management LLC 2,134 $4.97K 1.39% — 2026-09-30
10 Tower Research Capital LLC (TRC) Custodian 1,463 $550 0.15% — 2026-06-30
11 OSAIC HOLDINGS, INC. Custodian 100 $233 0.07% — 2026-09-30
12 SBI Securities Co., Ltd. 91 $212 0.06% — 2026-09-30
13 Rossby Financial, LCC 5 $12 <0.01% — 2026-09-30
14 TD Waterhouse Canada Inc. 2 $5 <0.01% — 2026-09-30
15 Citigroup Inc. Custodian 1 $2 <0.01% — 2026-09-30
16 Parallel Advisors, LLC 1 $2 <0.01% — 2026-09-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

BRTX Insider Trading (Form 4)

Latest: 2025-10-20
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2025-10-20 Lance Alstodt President, CEO, COB Award (A) +15,625 $1.60 $25.0K EDGAR
2025-10-20 Francisco Silva VP of Research and Development Award (A) +11,719 $1.60 $18.8K EDGAR
2025-02-19 David A Rosa Director Grant (A) +52,632 opt — EDGAR
2025-02-19 Lance Alstodt President, CEO, COB Award (A) — — EDGAR
2025-02-19 Nickolay V. Kukekov Director Grant (A) +52,632 opt — EDGAR
2025-02-19 Robert Eugene Kristal Chief Financial Officer Award (A) — — EDGAR
2025-02-19 Patrick F. Williams Director Grant (A) +52,632 opt — EDGAR
2025-02-19 Francisco Silva VP of Research and Development Award (A) — — EDGAR
2024-11-05 Dale Broadrick 10%+ Owner Sell (S) −1,112 $1.58 -$1.8K EDGAR
2024-04-10 Francisco Silva VP of Research and Development Buy (P) +8,308 $1.23 $10.2K EDGAR
2024-03-20 Lance Alstodt President, CEO, COB Tax (F) −17,633 $1.39 -$24.5K EDGAR
2024-03-20 Francisco Silva VP of Research and Development Tax (F) −17,193 $1.39 -$23.9K EDGAR
2024-02-15 Nickolay V. Kukekov Director Grant (A) +79,646 opt — EDGAR
2024-02-15 Robert Paccasassi VP, QA and Reg Compliance Grant (A) +219,298 opt — EDGAR
2024-02-15 Robert Eugene Kristal Chief Financial Officer Award (A) — — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

BRTX Insider Holdings

3 insiders · @ $1.31
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Lance Alstodt President, CEO, COB 9,375 $12.3K $124.9K 39 2025-10-20
2 Francisco Silva VP of Research and Development 9,176 $12.0K $116.4K 21 2025-10-20
3 Robert Eugene Kristal Chief Financial Officer 400 $524 $45.0K 8 2025-02-19
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

BRTX Board & Officers

As of SEC filings through Jul 30, 2026

Directors 6

  • Lance Alstodt · listed since Nov 2020
  • Jatinder Dhaliwal · since Jun 10, 2026
  • Katharyn Field · since Jun 10, 2026
  • Mika Grasso · since Jun 10, 2026
  • Esha Randhawa · since Jul 13, 2026
  • Steven Collier Brown · since Jul 14, 2026

Officers 1

10% owners 1

Changes in the last 10 years (34)
Jul 14, 2026Steven Collier Brown became a director
Jul 13, 2026The company announced the departure of David A Rosa from the board in an SEC filing
Jul 13, 2026Esha Randhawa became a director
Jun 10, 2026The company announced the departure of Patrick F. Williams from the board in an SEC filing
Jun 10, 2026The company announced the departure of Nickolay V. Kukekov from the board in an SEC filing
Jun 10, 2026Mika Grasso became a director
Jun 10, 2026Katharyn Field became a director
Jun 10, 2026Jatinder Dhaliwal became a director
Oct 20, 2025Lance Alstodt first listed as a 10% owner in an SEC filing
Oct 20, 2025Francisco Silva reported in an SEC filing no longer being a director
Oct 20, 2025Francisco Silva reported in an SEC filing no longer being VP of Research and Development
Feb 19, 2025Nickolay V. Kukekov first listed as a director in an SEC filing
Mar 20, 2024Lance Alstodt no longer listed as a 10% owner in SEC filings
Mar 20, 2024Francisco Silva no longer listed as a 10% owner in SEC filings
Feb 15, 2024Nickolay V. Kukekov reported in an SEC filing no longer being a director
Feb 17, 2023Lance Alstodt first listed as a 10% owner in an SEC filing
Feb 17, 2023Francisco Silva first listed as a 10% owner in an SEC filing
Nov 4, 2022Robert Paccasassi listed as VP, QA and Reg Compliance (previously VP, Quality and Compliance) in SEC filings
Nov 8, 2021Lance Alstodt no longer listed as a 10% owner in SEC filings
Nov 8, 2021Francisco Silva no longer listed as a 10% owner in SEC filings
Not reported recently (12)
  • Robert Eugene Kristal · Last reported as Chief Financial Officer in an SEC filing dated Feb 19, 2025
  • Dale Broadrick · Last reported as a 10% owner in an SEC filing dated Nov 5, 2024
  • Robert Paccasassi · Last reported as VP, QA and Reg Compliance in an SEC filing dated Feb 15, 2024
  • Mark Weinreb · Last reported as a director in an SEC filing dated Sep 6, 2019
  • Paul Jude Tonna · Last reported as a director in an SEC filing dated Sep 3, 2019
  • A. Jeffrey Radov · Last reported as a director in an SEC filing dated Aug 29, 2019
  • Robert B Catell · Last reported as a director in an SEC filing dated Mar 27, 2019
  • Mandy D. Clyde · Last reported as VP of Operations in an SEC filing dated Mar 26, 2019
  • Charles S. Ryan · Last reported as a director in an SEC filing dated Mar 25, 2019
  • John M Desmarais · Last reported as a director in an SEC filing dated Mar 25, 2019
  • Adam D. Bergstein · Last reported as SVP, Planning and Business Dev in an SEC filing dated Jan 19, 2018
  • Edward L. Field · Last reported as President brtxDISC Division in an SEC filing dated Jul 14, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-12
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-12 Director or officer change EDGAR
2026-10-09 Director or officer change EDGAR
2026-09-11 Director or officer change EDGAR
2026-09-02 Shareholder rights change · Bylaws or fiscal year change · Regulation FD disclosure EDGAR
2026-09-02 Auditor change · Director or officer change EDGAR
2026-08-25 Listing standards notice EDGAR
2026-08-14 Other events EDGAR
2026-07-16 Director or officer change EDGAR
2026-06-12 Director or officer change EDGAR
2026-06-12 Material agreement · Director or officer change EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
ETF Holders
1 ETF hold BRTX
1 shown · $3.03K total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VXF Vanguard Extended Market ETF Vanguard 0.00% $3,030 — 2026-10-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

BRTX vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
FMS Fresenius Medical Care AG $10.9B — — −14.3% 37
DVA DaVita Inc. $10.2B 11.5 +5.9% +36.1% 43
SHC Sotera Health Company Common Stock $4.7B 27.1 +6.9% −8.2% 38
PGNY Progyny, Inc. Common Stock $2.7B 32.5 +5.5% +37.8% 15
AGL agilon health, inc. $1.5B — +2.0% +423.6% 6
VMD Viemed Healthcare, Inc. Common Shares $333M 22.7 +21.8% +19.5% 36
QIPT Quipt Home Medical Corp. Ordinary Shares $162M — +8.3% +3.9% —
PARK Park Dental Partners, Inc. Common Stock $105M — — +23.7% —
BRTX BioRestorative Therapies, Inc. Common St $2M — — −94.6% —
Peer median $2.1B 24.9 +6.4% +21.6% 36

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.